Tigecycline is the first approved new glycyl intravenous antibiotics tetracycline, a broad-spectrum antimicrobial activity, for the treatment of Gram-negative or-positive pathogens, anaerobic organisms and methicillin-resistant Staphylococcus bacteria (MRSA) and methicillin-sensitive strains will Pu (MSSA) caused clA1, DSSSI, tigecycline to doctors to provide a new, early in treatment when the cause is unknown when the wide choice of antibiotics, and impaired renal function do not need to adjust the dose, easy to use, can be taken once every 12 hours. The most common adverse events were nausea (29.5%) and vomiting (9.7%). The antibacterial mechanism is by blocking aminoacyl tRNA into the ribosomal A-site and inhibit bacterial protein synthesis.
Read more: Buy A Tigecycline